Incyte Corporation (INCY) Bundle
A Brief History of Incyte Corporation (INCY)
Company Overview
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company founded in 1991. Ticker symbol: INCY, listed on NASDAQ.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $3.18 billion |
| Net Income | $546 million |
| Market Capitalization | $18.7 billion |
| Research & Development Expenses | $1.62 billion |
Key Product Portfolio
- Jakafi (ruxolitinib) - Primary treatment for myelofibrosis
- Pemazyre (pemigatinib) - Cholangiocarcinoma treatment
- Monjuvi (tafasitamab) - Lymphoma therapeutic
Research Focus Areas
Primary therapeutic domains:
- Oncology
- Inflammation
- Immunology
Stock Performance
| Year | Stock Price Range |
|---|---|
| 2023 | $55 - $82 per share |
| 2024 (as of February) | $67 - $75 per share |
Corporate Partnerships
- Eli Lilly and Company
- Novartis
- Merck & Co.
Who Owns Incyte Corporation (INCY)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 24,641,901 | 12.8% |
| BlackRock Inc. | 18,532,643 | 9.6% |
| FMR LLC | 16,453,721 | 8.5% |
| Capital World Investors | 14,623,900 | 7.6% |
Top Insider Ownership
- Hervé Hoppenot (President, CEO): 478,316 shares
- Christiana Stamoulis (CFO): 156,892 shares
- Paula Swann (EVP, Commercial): 112,543 shares
Ownership Breakdown
Institutional Ownership: 89.7%
Insider Ownership: 0.6%
Public Float: 9.7%
Top Mutual Fund Holders
| Fund | Shares | Value ($M) |
|---|---|---|
| Vanguard Total Stock Market Index Fund | 8,641,901 | 712.3 |
| Fidelity Contrafund | 5,612,743 | 462.5 |
| Capital Research Global Growth Fund | 4,523,900 | 372.6 |
Incyte Corporation (INCY) Mission Statement
Company Overview
Incyte Corporation (NASDAQ: INCY) is a biopharmaceutical company focused on developing innovative oncology and inflammation treatments. Headquartered in Wilmington, Delaware.
Financial Performance
| Metric | 2023 Value |
|---|---|
| Total Revenue | $3.47 billion |
| Net Income | $1.08 billion |
| Market Capitalization | $19.6 billion |
Research and Development Focus
- Oncology therapies
- Inflammation treatments
- Rare disease interventions
Key Product Portfolio
| Product | Indication | Annual Sales (2023) |
|---|---|---|
| Jakafi | Myelofibrosis | $2.1 billion |
| Pemazyre | Cholangiocarcinoma | $182 million |
Strategic Objectives
Primary mission: Develop innovative therapies addressing unmet medical needs in oncology and inflammatory diseases.
Research Investment
R&D Expenditure in 2023: $1.2 billion
Global Presence
- Operational headquarters in Wilmington, Delaware
- Research facilities in multiple locations
- Global commercial presence
How Incyte Corporation (INCY) Works
Company Overview
Incyte Corporation (NASDAQ: INCY) is a biopharmaceutical company headquartered in Wilmington, Delaware. As of 2024, the company focuses on developing oncology and inflammation treatments.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $3.17 billion |
| Net Income | $642 million |
| Research and Development Expenses | $1.42 billion |
| Market Capitalization | $17.3 billion |
Key Product Portfolio
- Jakafi (ruxolitinib) - Primary treatment for myelofibrosis
- Pemazyre (pemigatinib) - Cholangiocarcinoma treatment
- Monjuvi (tafasitamab) - Lymphoma therapy
Research and Development Focus
Incyte concentrates on developing targeted therapies in oncology and inflammation, with 47 active clinical trials as of 2024.
Geographical Presence
| Region | Number of Employees |
|---|---|
| United States | 1,850 |
| Europe | 350 |
| Asia-Pacific | 200 |
Strategic Partnerships
- Eli Lilly partnership for oncology research
- Novartis collaboration for development of JAK inhibitors
How Incyte Corporation (INCY) Makes Money
Revenue Streams
Incyte Corporation generates revenue primarily through pharmaceutical product sales and licensing agreements.
| Product/Revenue Source | Annual Revenue (2023) |
|---|---|
| Jakafi (Ruxolitinib) | $2.2 billion |
| Pemazyre (Pemigatinib) | $173 million |
| Monjuvi (Tafasitamab) | $238 million |
Key Product Portfolio
- Jakafi (Ruxolitinib) - Primary myelofibrosis treatment
- Pemazyre - Cholangiocarcinoma therapy
- Monjuvi - Diffuse large B-cell lymphoma treatment
Licensing and Collaboration Revenues
Incyte generates significant revenue through strategic partnerships with pharmaceutical companies.
| Partner | Collaboration Details | Potential Milestone Payments |
|---|---|---|
| Eli Lilly | Retifanlimab oncology collaboration | Up to $1.25 billion |
| Novartis | Capmatinib development | Up to $540 million |
Financial Performance
Incyte reported total revenue of $3.1 billion in 2023, with 71% derived from Jakafi sales.
- Total Revenue: $3.1 billion
- Net Income: $541 million
- Research & Development Expenses: $1.2 billion
Research and Development Strategy
Incyte invests heavily in oncology and inflammatory disease research.
| Research Area | Key Development Programs |
|---|---|
| Oncology | 6 clinical-stage programs |
| Inflammation | 3 clinical-stage programs |
Incyte Corporation (INCY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.